Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | MEN1 | O00255 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.96 |
| ▸ | GAA | P10253 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | TP53 | P04637 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975489 | 0.98 | MAPT (1.00) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL9382745 | 0.84 | MAPT (0.75) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL13912 | 0.84 | KMT2A (0.75) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL429085 | 0.84 | MAPT (0.75) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL4972639 | 0.84 | CYP1A2 (0.72) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL18294025 | 0.83 | HTT (0.75) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL532005 | 0.83 | KMT2A (0.73) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL7302053 | 0.83 | MAPT (0.73) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL30620451 | 0.83 | MAPT (1.00) | GFERCYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL14829004 | 0.81 | MAPT (0.71) | GFERCYP1A2CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2004064774-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-5580883-A | INHIBITING DEGENERATION AND NECROCYTOSIS OF CEREBRAL NERVE CELLS CAUSED BY OXIDATIVE STRESS INDUCING GLUTAMIC ACID IN MAMMALS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-03 | — | — | US | disclosed |
| EP-0449195-B1 | Aminobenzene compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0449195-A2 | Aminobenzene compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
| US-3956334-A | CHOLESTEROL AND TRIGLYCERIDE LOWERING ACTIVITY IN BLOOD | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | GFER 2676/4885CYP1A2 624/4885CYP3A4 826/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | GFER 2676/4885CYP1A2 624/4885CYP3A4 826/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | GFER 2944/4885CYP1A2 637/4885CYP3A4 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.